WO2016195377A3 - 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 - Google Patents

생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 Download PDF

Info

Publication number
WO2016195377A3
WO2016195377A3 PCT/KR2016/005810 KR2016005810W WO2016195377A3 WO 2016195377 A3 WO2016195377 A3 WO 2016195377A3 KR 2016005810 W KR2016005810 W KR 2016005810W WO 2016195377 A3 WO2016195377 A3 WO 2016195377A3
Authority
WO
WIPO (PCT)
Prior art keywords
pranlukast
composition
solid preparation
containing solid
preparing same
Prior art date
Application number
PCT/KR2016/005810
Other languages
English (en)
French (fr)
Other versions
WO2016195377A2 (ko
Inventor
이건희
김수진
안병길
박상만
황용연
Original Assignee
삼아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57441544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016195377(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 삼아제약 주식회사 filed Critical 삼아제약 주식회사
Priority to JP2017563225A priority Critical patent/JP2018516942A/ja
Priority to MX2017015505A priority patent/MX2017015505A/es
Priority to BR112017025793A priority patent/BR112017025793A2/pt
Priority to EP16803732.3A priority patent/EP3305282A2/en
Priority to CN201680032075.5A priority patent/CN108012526A/zh
Publication of WO2016195377A2 publication Critical patent/WO2016195377A2/ko
Publication of WO2016195377A3 publication Critical patent/WO2016195377A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)

Abstract

본 발명은 프란루카스트를 함유하는 약제학적 조성물 및 그 제조방법에 관한 것이다. 본 발명은 종래의 프란루카스트 함유 제품에 비해 프란루카스트의 용출률과 생체이용률이 현저하게 개선되었다는 것이 특징이다.
PCT/KR2016/005810 2015-06-01 2016-06-01 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 WO2016195377A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2017563225A JP2018516942A (ja) 2015-06-01 2016-06-01 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法
MX2017015505A MX2017015505A (es) 2015-06-01 2016-06-01 Composicion de preparacion solida que contiene pranlukast con biodisponibilidad mejorada y metodo para preparar la misma.
BR112017025793A BR112017025793A2 (pt) 2015-06-01 2016-06-01 composição de preparação sólida contendo pranlucaste com biodisponibilidade melhorada e método para preparar a mesma
EP16803732.3A EP3305282A2 (en) 2015-06-01 2016-06-01 Composition of pranlukast-containing solid preparation with improved bioavailability and method for preparing same
CN201680032075.5A CN108012526A (zh) 2015-06-01 2016-06-01 具有改进的生物利用度的含普仑司特固体制剂的组合物及其制备方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0077587 2015-06-01
KR1020150077587A KR102363727B1 (ko) 2015-06-01 2015-06-01 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법

Publications (2)

Publication Number Publication Date
WO2016195377A2 WO2016195377A2 (ko) 2016-12-08
WO2016195377A3 true WO2016195377A3 (ko) 2017-01-26

Family

ID=57441544

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/005810 WO2016195377A2 (ko) 2015-06-01 2016-06-01 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법

Country Status (8)

Country Link
EP (1) EP3305282A2 (ko)
JP (1) JP2018516942A (ko)
KR (1) KR102363727B1 (ko)
CN (1) CN108012526A (ko)
BR (1) BR112017025793A2 (ko)
MA (1) MA43122A (ko)
MX (1) MX2017015505A (ko)
WO (1) WO2016195377A2 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108686252B (zh) * 2018-06-11 2021-05-18 深圳英凡妮生物科技有限公司 一种以壳聚糖-泊洛沙姆为基质的纳米银抗菌敷料及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100389606B1 (ko) * 1995-06-12 2003-09-26 오노 야꾸힝 고교 가부시키가이샤 프란루카스트를함유하는조립물,그제조방법및프란루카스트의부착응집성개선방법
KR20070045799A (ko) * 2005-10-28 2007-05-02 주식회사유한양행 프란루카스트를 함유하는 과립 및 그의 제조방법
KR100957731B1 (ko) * 2005-04-11 2010-05-12 오노 야꾸힝 고교 가부시키가이샤 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
KR20110029249A (ko) * 2009-09-15 2011-03-23 김기탁 프란루카스트의 향상된 용해도를 갖는 약학적 조성물
KR101125087B1 (ko) * 2005-12-16 2012-03-21 오노 야꾸힝 고교 가부시키가이샤 약물 포장체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101086254B1 (ko) 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
KR20080071557A (ko) * 2005-11-24 2008-08-04 오노 야꾸힝 고교 가부시키가이샤 고형 제제 및 제제 조성물
KR101332223B1 (ko) 2011-09-19 2013-11-25 충남대학교산학협력단 프란루카스트 나노 고체 분산체의 제조방법 및 이로써 제조된 나노 고체 분산체
KR101446129B1 (ko) 2012-10-10 2014-10-06 조선대학교산학협력단 프란루카스트-함유 고형 제제의 제조방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100389606B1 (ko) * 1995-06-12 2003-09-26 오노 야꾸힝 고교 가부시키가이샤 프란루카스트를함유하는조립물,그제조방법및프란루카스트의부착응집성개선방법
KR100957731B1 (ko) * 2005-04-11 2010-05-12 오노 야꾸힝 고교 가부시키가이샤 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제
KR20070045799A (ko) * 2005-10-28 2007-05-02 주식회사유한양행 프란루카스트를 함유하는 과립 및 그의 제조방법
KR101125087B1 (ko) * 2005-12-16 2012-03-21 오노 야꾸힝 고교 가부시키가이샤 약물 포장체
KR20110029249A (ko) * 2009-09-15 2011-03-23 김기탁 프란루카스트의 향상된 용해도를 갖는 약학적 조성물

Also Published As

Publication number Publication date
BR112017025793A2 (pt) 2018-08-07
CN108012526A (zh) 2018-05-08
MX2017015505A (es) 2018-05-11
KR102363727B1 (ko) 2022-02-16
KR20160141620A (ko) 2016-12-09
EP3305282A2 (en) 2018-04-11
JP2018516942A (ja) 2018-06-28
MA43122A (fr) 2018-09-05
WO2016195377A2 (ko) 2016-12-08

Similar Documents

Publication Publication Date Title
EP3402787A4 (en) PROCESSES FOR PREPARING 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF
WO2015110897A3 (en) Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof
WO2015104658A3 (en) Amorphous solid dispersion of dapagliflozin and process for the preparation of amorphous dapagliflozin
EP3262029A4 (en) Method for the preparation of metal-organic compounds
EP3279207A4 (en) Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
WO2015191945A3 (en) Solid state forms of sofosbuvir
WO2016125191A3 (en) Processes for the preparation of vortioxetine hydrobromide
EP3694499A4 (en) NEW LIFITEGRAST PREPARATION PROCESS
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
HUP1500618A2 (en) Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
WO2015181802A3 (en) Oral pharmaceutical composition of isotretinoin
EP3303320A4 (en) Novel heterocyclic compound, method for preparing the same, and pharmaceutical composition comprising the same
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
EP3406254A4 (en) APPLICATION OF FULLERENE / METAL-FULLERENE FOR THE PREPARATION OF A PHARMACEUTICAL PRODUCT
EP3727377A4 (en) PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS
WO2015095659A3 (en) Indirubin solid dispersion composition
WO2016195377A3 (ko) 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법
WO2017029642A3 (en) Novel polymorphs of dolutegravir and salts thereof
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2017222819A3 (en) Solid state forms of ixazomib citrate
WO2017046816A3 (en) Process for the preparation of derivatives of benzodioxole
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
EP3436439A4 (en) METHOD FOR PRODUCING DIPHENYLPYRAZINE DERIVATIVES

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16803732

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017563225

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/015505

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2016803732

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017025793

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112017025793

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20171130